// App-Quantinova.ai

: Azurocidin-1: a marker of COPD severity and microbial dysbiosis

Researchers

Presenter

  • Jennifer Pollock

Principal Investigators

  • Alison Dicker

  • Mike Lonergan

  • Holly R Keir

  • Alexandria H Smith

  • Megan Crichton

  • Jeffrey T-J Huang

  • Bruce E Miller

  • Ruth Tal-Singer

  • James D Chalmers

Medical Centers

  • University of Dundee, Dundee, United Kingdom

  • Medical Innovation Value Evidence and Outcomes GSK R&D, Collegeville, United States of America

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Endocrine/metabolic Diseases (ME)

Disease

  • Dysbiosis

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • azurocidin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved